HC Wainwright Has Bullish Estimate for CARM FY2024 Earnings

Carisma Therapeutics, Inc. (NASDAQ:CARM) – Analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Carisma Therapeutics in a report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.32) for the year, up from their previous forecast of ($1.33). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Carisma Therapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Carisma Therapeutics’ Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.00) EPS.

Separately, EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock opened at $0.85 on Wednesday. The company’s 50 day simple moving average is $0.97 and its 200-day simple moving average is $1.10. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. Carisma Therapeutics has a 1 year low of $0.80 and a 1 year high of $3.16. The company has a market capitalization of $35.49 million, a price-to-earnings ratio of -0.54 and a beta of 1.49.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). The firm had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%.

Institutional Trading of Carisma Therapeutics

Several hedge funds have recently made changes to their positions in the business. Wexford Capital LP grew its holdings in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics in the second quarter worth $40,000. Barclays PLC increased its position in shares of Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after acquiring an additional 11,200 shares in the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.